The Imaginary Worlds of Cure Proportion Modeling:  Survivorship and Reference Case Pricing of Transformative Therapies by Langley, Paul
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                       2019, Vol. 10, No. 3, Article 17                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i3.2241 
1 
 
The Imaginary Worlds of Cure Proportion Modeling:  Survivorship and Reference Case 
Pricing of Transformative Therapies 
Paul C Langley, PhD  
Adjunct Professor, College of Pharmacy, University of Minnesota 
 
 
 
Abstract 
On August 6, 2019 the Institute for Clinical and Economic Review (ICER) released a set of proposed adaptations to its value assessment 
framework methods where the intervention under review was considered a ‘single or short-term transformative therapy’ (SST). These 
adaptations are intended to ‘complement and build upon the upcoming update to the overall ICER assessment framework…’.  The 
purpose of this commentary is to review the proposed cure proportion modeling reference case framework for assessing the value of 
SSTs together with ICER’s ‘recommendations for fair value-based pricing …’. Following previous commentaries on the ICER value 
assessment framework, the question raised is whether the proposed cure proportion modeling standards meet those of normal science:  
is the modeling proposed capable of generating value claims for the intervention that are credible, evaluable and replicable? The 
proposed standards for transformative therapies do not change the underlying commitment to reference case modeling. At the same 
time, the cure proportion modeling proposed adaptations have to be seen in the context of the concerns expressed by ICER that their 
reference case model can be used to justify substantial one-off SST pricing. This follows from the ICER incremental cost per QALY 
willingness to pay thresholds where the SST QALY gains are sufficient, at even a $50,000 QALY cut-off, to support SST pricing in the 
millions of dollars. ICER has two options: (i) abandon the imaginary reference case methodology, which is the ICER core business model 
and would represent an ironic reversal, or (ii) attempt to bolt-on adaptations, possibly incorporating revised survivorship profiles using 
cure proportion modeling, that supports a modified imaginary reference case ‘rescue’ model for SSTs designed specifically to generate 
pricing recommendations that may be considered affordable. 
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Introduction 
On August 6, 2019 the Institute for Clinical and Economic 
Review (ICER) released a proposed set of standards for value 
assessment methods for short-term or transformative 
therapies (SSTs) together with a technical brief on value 
assessment for potential cures 1 2. These standards are to be 
seen as adaptations to the ICER value assessment framework. 
ICER posted these proposed standards with a one-month public 
comment period. ICER would then ‘reflect’ on comments 
received, seek further feedback from stakeholders with its final 
version of the standards to be posted by end-2019.    
 
The purpose of this commentary is to review and reply to these 
proposed standards for SST value assessment. Publishing in the 
public domain is seen as the most effective way of ensuring 
both transparency in the review process as well as making the 
review available to a wider audience within the US health care 
system. Given the role ICER has taken upon itself as the arbiter 
of value assessments and pricing recommendation in the US, a 
public debate is critical as there are substantial and fatal 
objections to the ICER value assessment methodology. Putting  
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these concerns in the public domain follows upon previous  
commentaries in INNOVATIONS in Pharmacy on ICER evidence 
reports and associated technical assessments. These have 
raised the question of whether the ICER modeled reference 
case meets the standards of normal science 3 4 5 6 7 8 9 10. If, as 
argued below, the ICER reference case methodology, which 
applies across the board and not only to SSTs, is judged not to 
meet the standards of normal science then this should be made 
clear to health system decision makers and the wider public to 
include pharmaceutical manufacturers.  
 
A particular concern is to review how ICER might propose to 
respond to the fact that, in the case of SSTs where a one-off cure 
is possible, the reference case model is consistent with pricing 
for SSTs which ICER and others might consider exorbitant. This 
follows, within the reference case framework, from the 
substantial QALY gains attributable to SSTs. If ICER is to continue 
to subscribe to the reference case methodology meme, which 
after all is its core business model, then adaptations such as core 
proportion modeling might be seen as a framework for 
addressing what ICER sees as the potential for exorbitant pricing 
with manufacturers assumed to be building a surplus (i.e., a rent 
component) into the price of the SST.   
 
Meeting the Standards of Normal Science 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for products and devices 
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is unexceptional. Since the 17th century it has been accepted that 
if a research agenda is to advance, if there is to be an accretion 
of knowledge, there has to be a process of discovering new facts. 
Indeed, as early as the 16th century Leonardo da Vinci (1452 – 
1519) in notes that appeared posthumously in 1540 for his 
Treatise on Painting (published in 1641) clearly anticipated the 
standards for the scientific method which were widely embraced 
a century later in rejecting thought experiments that fail the test 
of experience. By the 1660s, the scientific method, following the 
seminal contributions of Bacon, Galileo, Huygens and Boyle, had 
been clearly articulated by associations such as the Academia del 
Cimento in Florence (1657) and the Royal Society in England 
(founded 1660; Royal Charter 1662) with their respective mottos 
Provando e Riprovando (prove and again prove) and nullius in 
verba (take no man’s word for it) 11.  
By the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 12 13 .  Hypotheses or claims must be capable of 
falsification; indeed they should be framed in such a way that 
makes falsification likely. Life becomes more interesting if claims 
are falsified because this forces us to reconsider our models and 
the assumptions built into those models. This leads, then, to the 
obvious point that claims or models should not be judged on the 
realism or reasonableness of assumptions or on whether the 
model ‘represents’ for a public advocacy research group such as 
ICER their perception of a future, yet unknown, reality.  
Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) is 
now seen an oversimplification involving more than just the 
criteria of falsification, the demarcation problem remains 14.  
Certainly, there are different ways of doing science but what all 
scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. 
Indeed, paradoxically, while the development of pharmaceutical 
products and the evidence standards required by the Food and 
Drug Administration (FDA) for product evaluation and marketing 
approval is driven by adherence to the scientific method, once a 
product is launched and claims made for cost-effectiveness and, 
in the case of ICER, pricing and access recommendations, the 
scientific method is put to one side.  Pseudoscience succeeds 
science. 
The rejection of a research program that meets the standards of 
normal science by groups such as ICER is best exemplified by the 
latest version of the Canadian health technology guidelines 
where it is stated: Economic evaluations are designed to inform 
decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses 15. While this 
position puts modeled health technology assessment in the 
category of pseudoscience, it is also what may be described as a 
relativist position. Rather than subscribing to the position that  
the standards of normal science are the only standards to apply 
in health care decisions and value claims, the relativist believes 
that all perspectives are equally valid. Health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a lifetime modeled simulation are 
on an equal basis with those of a pivotal Phase 3 randomized 
clinical trial. For the relativist, the success of a scientific research 
program, in this case one built on hypothetical models and 
simulations, rests not on its ability to generate new knowledge 
but on its ability to mobilize the support of the community. 
Basing decisions on models and simulations underpins the 
consensus view that evidence is constructed, never discovered. 
Instead of coming to grips with reality, science is about rhetoric, 
persuasion and authority 11. Truth is consensus. 
 
Models and Assumptions 
It is accepted that knowledge is provisional and permanently 
so. This stems from the obvious point that we can at no stage 
prove that what we ‘know’ is true. Attempting to believe or 
justify our belief in a theory is logically impossible. What we can 
do, by empirical assessment, is to try and demonstrate our 
preference for one theory over another (and apply it to the best 
of our knowledge).  
 
Constructing imaginary worlds which were never intended to 
generate potentially falsifiable claims cannot, therefore, be 
defended by an appeal to the ‘truth’ of their assumptions. If a 
health technology assessment claim is built upon a series of 
assumptions, a reasonable question is to ask what is the status 
of the various assumptions? Are they to be viewed as 
‘reasonable or ‘realistic’ metrics for an unknown future reality?  
Have they been selected from the literature because they seem 
appropriate? Is there a belief that the fact that they are based, 
where feasible, on an empirical study validates the choice of 
assumption? For example, if the model is intended to 
incorporate utilities that have been reported in one or two 
studies (usually as few as that) for progression and time spent 
in the stages of a disease, then there is an immediate 
methodological issue. To claim that an assumption is valid is to 
revisit Hume’s problem (David Hume 1711-1776): induction – 
an appeal to facts to support a scientific statement. 
Unfortunately, as Hume pointed out, no number of singular 
observations can logically entail an unrestricted general 
statement. Certainly, there may be comfort in reporting that ‘so 
far’ the claim that all swans are white has not been contradicted 
(until that vacation in Western Australia) so that one fully 
expects the next swan to be white. But as Hume also pointed 
out, this is a fact of psychology and does not entail any general 
statement. From a utility perspective, the fact that one hundred 
papers have agreed (within limited bounds) generic utilities 
from the same instrument for a target population in a disease 
state stage is immaterial. We cannot secure this assumption: it 
cannot be ‘established by logical argument, since from the fact 
that all past futures have resembled past pasts, it does not 
follow that all future futures will resemble future pasts’ 16.  
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Claims, for the relevance of a constructed imaginary world built 
on the assumption that the model elements have been 
validated by observation is simply nonsensical.  
 
Despite ICER’s continued embrace, logical positivism is dead. It 
died some 80 years ago. All knowledge is provisional. Poppers 
contribution was to make clear that Hume’s problem with 
induction can be resolved. We cannot prove the truth of a 
theory, or justify our belief in a theory or attendant 
assumptions, since this is to attempt the logically impossible. 
We can only justify our preference for a theory by continued 
evaluation and replication of claims. Constructing imaginary 
worlds, even if the justification is that they are ‘for information’ 
is, to use Bentham’s (Jeremy Bentham (1748-1832) memorable 
phrase ’nonsense on stilts’. If there is a belief, as subscribed to 
by ICER, in the sure and certain hope of constructing imaginary 
worlds, to drive formulary and pricing decisions, then then it 
needs to be made clear that this is a belief that lacks scientific 
merit. 
 
A final point: given the emergence of ICER in the mid-2000s, a 
reasonable question is whether, following the popularity of 
reality TV shows, ICER should be seen as a reality show. After 
all, Poniewozik, in his assessment makes the point that Survivor, 
one of the most popular, is also ‘a masterpiece of applied 
postmodernism, a faux reality built entirely from simulacra of 
the real world, an imitation of life more satisfying and pliant to 
the creator’s will than reality itself could ever be’ 17.  
 
The ICER Reference Case 
Central to the ICER construction of imaginary value claims is the 
reference case. Standards for model building, the construction 
of imaginary worlds, are clearly stated with the preference for 
models that take a long-term or lifetime perspective. Value 
propositions are in imaginary cost-per QALY terms. Once an 
imaginary cost-per-QALY estimate (or estimates under different 
scenarios) has been constructed, the acceptability of a 
proposed product price is then assessed against cost-per-QALY 
willingness to pay thresholds (typically $50,000, $100,000 and 
$150,000 per QALY with exceptions for higher cut-offs for rare 
diseases). Whether a product ‘adds value’ is then determined 
in terms of its impact on an imaginary estimated lifetime 
modeled QALYs set against a proposed lifetime product cost 
where both are driven by hypothetical constructed evidence.  
 
Unfortunately, the position taken by the Canadian guidelines 
reflects the consensus view in health technology assessment as 
reflected in ICER imaginary constructs. Over the past 30 years, 
literally thousands of modeled claims have been presented in 
the literature, including leading health technology assessment 
journals. Annual reviews of the status of cost-effectiveness or 
modeled claims in the three journals, Pharmacoeconomics, 
Value in Health and the Journal of Medical Economics found 
that the majority of models presented non-evaluable claims 
(typically lifetime cost-per-QALY) 18 19 20 21 22. Where models 
were funded by a manufacturer a high proportion supported, in 
their modeled cost-per-QALY assessment, the manufacturer’s 
product. All too many of the papers were essentially marketing 
exercises 23 24.  
 
Transformative Therapies and Adaptive Strategies 
The ICER reference case framework fails to meet the standards 
of normal science. The claims made lack credibility. They are 
neither evaluable nor replicable. The proposed adaptive 
strategies for modeling SSTs, through a modified version of the 
survivorship modeling, that are ‘not mature enough to 
determine a   reference case’, similarly fail to meet those 
standards.  
 
ICER proposes, as a first step, to determine which single and 
short-term SSTs are appropriate for the proposed adaptive 
modeling approach to value assessments. For ICER’s purposes 
the SSTs are defined as ‘therapies that are delivered through a 
single intervention or a short-term course of treatment that 
demonstrates a significant potential for substantial and 
sustained health benefits extending throughout patients’ 
lifetimes’. Two subcategories of SST are identified: (i) potential 
cures that eradicate a disease or condition; and (ii) 
transformative therapies that produce sustained major health 
gains or halt progression of significant illnesses.  
 
The focus of the proposed adaptive strategies is the application, 
where deemed relevant by ICER, of cure proportion modeling of 
survivorship where a ‘proportion of patients may be expected to 
be cured or benefit from a complete halt in the progression of a 
serious illness’. If the data support a cure proportion survival 
curve with a sustained plateau’ scenario analyses utilizing 
various survival analytical techniques will be applied to 
characterize plausible results (emphasis added). ICER proposes 
to develop a range around estimated survival until ‘more data 
become available’. Two points to note: (i) who decides on 
‘plausibility’ and (ii) at what stage does ICER propose to revisit its 
imaginary construct to create, presumably, another imaginary 
world? 
 
Following public comment, ICER will, as arbiter, make the final 
decision on whether a treatment meets its SST criteria. The key 
elements of the reference case model are retained with 
Incremental cost-effectiveness scenarios and value based prices 
for multiple time horizons with the overall benchmark the 
standard lifetime horizon of the official ICER value-based 
benchmark. In both instances, therefore, the base case is the 
construction of the reference case imaginary world over the 
projected lifetime of a hypothetical patient cohort. Neither the 
SST adaptation nor the standard ICER value based price 
benchmarks are intended to generate evaluable claims. The 
modeled outcomes are entirely speculative and are, presumably, 
for ‘information only’.  
 
As evidence for durability of an SST effect will typically not be 
available, ICER will provide modeled information ‘on how cost-
effectiveness and value-based prices would be impacted under 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                       2019, Vol. 10, No. 3, Article 17                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i3.2241 
4 
 
various assumptions about durability of effect’. ICER will, 
however, retain the lifetime horizon as its value-based 
benchmark basis.  Whether decision makers will find these 
various imaginary ‘information’ scenarios’ useful is a moot point. 
A major concern is that in accepting the various ICER durability 
scenarios and their corresponding value assessments decision 
makers may be unaware of the cumulative impact of ICER’s value 
judgements and choice of assumptions that lie behind the 
various scenarios. After all, it is unlikely that the majority of 
health system decision makers in the US will be familiar with the 
strengths and weakness of the options in cure proportion 
survivorship projections or the fallback techniques that ICER may 
apply where the data are ‘not mature’ – whatever that means - 
or the criteria ICER has applied to give a seal of approval to the 
‘maturity’ of the data.  Again, ICER asks its audience to ‘take their 
word for it’ where this could refer, not only to an ICER preferred 
model (with attendant sensitivity analyses and probability 
claims), but the possible creation of competing models by 
interested parties (also with their attendant sensitivity analyses 
and probability claims) as additional ‘information’ for health 
system decision makers. Once we admit the role of imaginary 
worlds in health technology assessment, our imagination can 
create, in principle, a multiverse of competing worlds; none of 
which should be taken seriously..   
 
It is not clear what criteria will ICER apply in its decision to apply 
the adaptive model. One option, of course would be to admit 
that the data are insufficient to support any application of 
survivorship techniques. Unfortunately, this would mean that 
ICER would have to abandon the reference case and any cost-
per-QALY value claims. This is unlikely. ICER’s response will be to 
develop incremental cost-effectiveness scenarios, even in the 
absence of robust survivorship estimates, at multiple time 
horizons at the time horizon representing the longest-available 
follow-up data and also at 5 years, 10 years, 15 years and   the 
standard lifetime horizon.  
 
Hoisting and Petards 
Although the focus in the ICER proposed adaptations is on cure 
proportion modeling, there is a more substantive issue regarding 
the need to modify QALY based claims where the reference case 
model is the framework for SST claims. This is the scenario 
where, due to the substantial QALY incremental gains potentially 
attributable to SST therapies, the ICER reference case model can 
support pricing strategies by SST manufacturers that, while seen 
as exorbitant by groups such as ICER, are consistent with the 
willingness to pay threshold values of the reference model. 
Taken at face value, this puts ICER is an embarrassing situation. 
While the reference case model has been applied over the past 
decade or more by ICER to support price discounting 
recommendations, the same model can be used to support SST 
therapy pricing that may run to millions of dollars for a single 
cure application.  
 
In the 1604 second quarto version of Hamlet Shakespeare has 
Hamlet telling his mother: 
Let it work,  
For ’tis the sport to have the engineer 
Hoist with his own petard; and’t shall go hard 
But I will delve one yard below their mines 
And blow them at the moon. O, tis most sweet  
When in one line two crafts directly meet25 
 
Whilst omitted from the first quarto and the first folio, the 
phrase ‘Hoist with his own petard’ has resonated in the English 
language. Although ICER and other health technology 
assessment groups are hardly to be equated with the mission 
directed by Claudius for Rosencrantz and Guildenstern, it has 
become proverbial in capturing an event of ironic reversal or 
poetic justice. For ICER, and other commentators, attempts to 
model the QALY gains from the application of SSTs over the 
lifetime of the patients have the potential to justify substantial 
single prices for SST cure interventions.  While ICER has been 
comfortable in assessing QALY incremental gains for chronic 
therapies in a range of disease states in cost per QALY terms, the 
gains have typically been small. Hence modeled imaginary 
worlds have delivered recommendations for significant price 
discounting where costs have exceeded willingness to pay 
thresholds. With SSTs the position is reversed: the modeled 
imaginary QALY gains are such that substantial one-off or short-
term cure prices can be justified by application of conventional 
modeled willingness to pay thresholds.  
 
Consider, to illustrate the issue faced by ICER and others who 
subscribe to a lifetime reference case framework for creating 
imaginary treatment impact, the following example. If a 
company develops a single-application gene ‘cure’ in a rare 
disease, the scenario changes from a limited survival expectancy 
with a low health related quality of life under standard care. 
After treatment, the patient can presumably (by assumption) 
look forward to a ‘normal life’ with, for example, incremental 
modeled discounted QALYS in a hypothetical range of 30 to 50 
years or more. If we take the lower bound of 30 QALYs than, to 
meet a willingness to pay threshold of $50,000 (the lowest of the 
three typically modeled by ICER) then a manufacturer could set 
a one-off treatment price marginally less than $1.5 million 
($50,000 per QALY) and meet the reference case benchmark for 
ICER’s seal of approval for pricing. Even if cost-offsets were 
included the picture would not change materially. 
Manufacturers could justify the pricing policy on the grounds 
that they are subscribing to state of the art modeling as 
advocated by ICER and other professional groups.  
 
The challenge, as presumably seen by ICER, is to attempt to 
maintain its commitment to imaginary lifetime reference case 
evidence creation while proposing possible ‘methods 
adaptations’ to the current standard assessment approaches to 
accommodate SST pricing. Central to ICER’s concerns is the belief 
that there needs to be a mechanism that claws back a ‘pricing 
surplus’ that is believed to be an element in the SST pricing 
structure.  Unfortunately, as ICER recognizes, there is no obvious 
solution to address either what ICER sees as probably 
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unacceptable SST pricing. The issue ICER has to face is that its 
reference case evidence construction fails to meet the standards 
of normal science. Where evidence is constructed by assumption 
in the ICER reference case or its proposed adaptive SST version, 
there is no fallback position. A pricing surplus might be assumed, 
but no evidence presented to support a quantitative assessment 
across the range of SST therapies. Are we, therefore, to cherry 
pick a model framework, either versions of the reference case 
model or versions of possible adaptive cure proportion models 
to support ICER conclusions and recommendations for SST 
pricing?  
 
Proposals by ICER for possible innovative payment mechanisms  
‘to manage the tensions between high prices and payers’ need 
to maintain affordability’ rest on the willingness of health 
decision makers to accept ICER imaginary modeled claims under 
the ICER selected adaptive SST framework. One proposal put 
forward is for price caps. ICER rejects this on the grounds that a 
price cap may penalize SST manufacturers, shifting incentives 
towards investment in chronic therapies. Other proposals are for 
rate of return pricing and for shared savings where the value of 
cost offsets generated by SSTs would be shared. Again, any 
agreement for shared savings would have to agree (i) the offset 
savings for the health system as contracting party and (ii) the 
distribution of savings. These would presumably require a 
monitoring agreement. If the argument is extended to include an 
agreement to share in the so-called surplus, ICERs problems are 
compounded. First, there is no evidence to support the 
hypothesis that manufacturers include a ‘surplus component’ 
into their pricing policy (if the notion is even entertained). 
Second, if ICER believes that there is a surplus component (i.e., 
economic rent), it would be virtually impossible to provide an 
estimate. ICER would have to demonstrate that they can provide 
a validated algorithm to generate estimates of the proposed 
(and mythical) surplus component in one- off pricing that applies 
across cure therapies in multiple disease areas. 
 
ICER is in an awkward position. After over a decade of therapy 
intervention assessment, building claims for price adjustments 
with evidence from the reference case guide to the construction 
of imaginary worlds, the reference case has become a liability. 
Unless ICER can convince health system decision makers that the 
reference case should be put to one side as a basis for pricing 
recommendations for one-off ‘cure’ therapies, doubt is cast on 
the application of the reference case framework across multiple 
disease states.  
 
The irony of the situation is that in following groups such as 
ISPOR, NICE and CADTH, ICER joins them in applying a reference 
case framework that can be used to justify, on ICER’s terms, a 
one-off ‘cure’ price that ICER considers excessive. Indeed, in 
these cases it is also ironic to consider that manufacturers of 
one-off cures could utilize a reference case model to establish a 
pricing structure that meets ICER’s willingness–to-pay standards. 
It is also not clear that the one-off pricing structures are 
necessarily exploitive (i.e., rent seeking). In the absence of an 
assessment by a third party of the costs of ‘cure’ drug 
development it is impossible to make any claim for a ‘surplus’. 
To assume that a surplus exists is simply irresponsible. Of course, 
the irony of the situation does not extend just for one-off cures. 
There may be in the drug development pipeline chronic 
therapies that yield similar QALY gains. In which case ICER is also 
placed in an impossible situation in attempting to maintain the 
integrity of it’s of claims from imaginary worlds. Perhaps, as the 
Hamlet stage directions might detail: exeunt ICER with imaginary 
worlds. 
 
Survivorship, Utilities and QALYS 
A recent commentary on the ICER final evidence report for 
Duchenne muscular dystrophy (DMD) pointed to the limitations 
for the ICER reference case in the choice of QALY measures 26. It 
was noted that while ICER appears to follow the NICE reference 
case in recommending (if not mandating) a standard generic 
measures (e.g. EQ-5D-5L) for QALY assessments by stage of a 
chronic disease, the commitment is less clear cut.  
 
Putting to one side the obvious objection that the lifetime QALY 
claims are entirely speculative and fail the standards for 
demarcation of science from pseudoscience, it appears that in 
the case of DMD ICER simply takes the ‘only available’ utility 
measure, irrespective of its demonstrated ability to capture 
relevant aspects of quality of life (QoL) or, more narrowly, health 
related quality of life (HRQoL) in DMD. ICER is not interested in 
investing resources to generate appropriate QoL or HRQoL 
instruments for the target disease areas. Even if those resources 
were invested in a timeframe appropriate to the future ICER 
assessment schedule, the effort would be questionable given 
that the ICER reference case is not designed to test hypotheses. 
 
As ICER points out, at the time of marketing approval and 
product launch the evidence base, and this is not unique to SSTs, 
is often limited.  Unfortunately, as demonstrated by past ICER 
reports, all too little attention is given to the weaknesses of the 
evidence base with ICER doggedly going forward to make a 
modeled value assessment that rests on unsupported or dubious 
assumptions. This applies in particular to the measurement of 
utilities appropriate to the target patient population. In many 
cases there is no validated utility instrument for the target SST 
that captures the key attributes of the experience of patients, 
providers, caregivers and the wider family environment.  
Instead, ICER falls back upon published utility scores that fail to 
capture the attributes of interest for treatment impact, notably 
generic scores from instruments such as the EQ-5D-5L, the SF-6D 
and HUI Mk3. Duchenne muscular dystrophy is a classic example 
where their application in a reference case model is clearly 
inappropriate.  
 
In the case of SSTs, ICER faces more intractable issues if it 
pursues the reference case paradigm. The fact is that, apart from 
making assumptions regarding the QoL or HRQoL of ‘cure’ 
patients subsequent to the therapy intervention, or for mixed 
models where only a proportion of patients respond to the ‘cure’ 
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intervention, there is no evidence base to justify ICERs 
‘measured’ QALYs. While this does not imply acceptance of the 
ICER imaginary world lifetime reference case, ICER recognizes in 
the discussion paper that in there may be ‘additional dimensions 
of value’ that ‘should be systematically considered in the 
evaluation of all new therapies’. These include real option value, 
the value of hope and insurance value. Although not addressed 
by ICER there are a range of other issues specific to patients, 
caregivers and their families that need to be canvassed. ICER is 
not, at the moment, apparently interested in more ‘robust’ QoL 
or HRQoL measures with ICER putting them them to one side as 
premature. 
 
Given the reference case model, ICER needs to come to terms 
with the issue of utility measurement. It is one thing to cobble 
together a reference model from ’available data’ and another to 
address the question of the appropriate and defensible 
measurement of QoL or HRQoL relevant to the disease state. In 
the case of SSTs, ICER needs to propose standards for the utility 
scores relevant to stages of a disease and the experience of 
QALYs in the post-cure target population. The concern, for those 
subscribing to the information role of imaginary constructs, is 
that audiences for ICER SST reports and the supporting imaginary 
modeled claims, will have little faith in the case put forward to 
justify pricing for SSTs or options for ‘shared savings’ driven by 
constructed evidence and potentially questionable choice of QoL 
or HRQoL measure.  
 
Quis custodiet ipsos custodies 
Even though the ICER reference case methodology fails to meet 
the standards of normal science, there can be little doubt that 
ICER will attempt to defend its position. After all, its business 
case rests upon the construction of imaginary worlds with the 
apparent willingness of health system decision makers to take 
the modeled value claims at face value. Given this, and with 
ICER’s self-appointed guardian role in value assessment for the 
US health care system, it is important that ICER is as transparent 
as possible in interacting with stakeholders. If ICER is to maintain 
its credibility in the construction of imaginary worlds it needs to 
make clear the limitations inherent in its reference case 
methodology.    
• ICER should make clear in all reports that the modeled 
reference case with the base case lifetime or long-term 
perspective does not meet the standards required for 
normal scientific inquiry in the construction of empirically 
evaluable theories and hypotheses; 
• ICER should make clear that its imaginary modeled 
recommendations are always provisional and all too often 
rest on a limited evidence base. Given this, ICER could 
commit to a regular review of its models (e.g., every two 
years) as new data become available following product 
launch to recast the model structure and assumptions. As 
there is no basis for saying this is now a more ‘realistic; 
picture of an unknown future ’reality’; the result would be 
simply a succession of modeled imaginary worlds with 
each seen as the latest ‘provisional’ construct;  
• ICER should make clear that it sees its value assessments 
as potentially informing health care decisions and that, as 
stated clearly in the CADTH guidelines that follow an 
identical reference case methodology, the ICER  value 
assessments are ‘distinct from conventional research 
activities, which are designed to test hypotheses’; 
• ICER should make clear that the reference case 
framework can support any number of competing value 
assessment models and that attempts to differentiate and 
claim one model is ‘superior’ to another can only rely on 
an assessment of the assumptions made in constructing 
the imaginary world; 
• ICER should make clear that any claims for ‘value’ based 
on notional cost per QALY willingness to pay thresholds 
are not only impossible to evaluate but that they were 
never intended to meet the standards of normal science 
and were therefore never intended to be evaluated - 
which would be impossible over the timeline of the 
model.  
 
Conclusions: Nullius in Verba 
Does ICER have a significant or serious role in the pricing and 
allocation of health care interventions in the US health care 
system? Unless a case can be made for the information content 
of imaginary constructs as a recognized input to decision making, 
the answer is clearly, no. Irrespective of claims by ICER that their 
modeling is reflective of the ‘state of the art’ modeling endorsed 
by professional groups such as ISPOR, the ICER business case that 
rests on creating imaginary worlds across disease areas, fails the 
demarcation test; it is pseudoscience.  
 
ICER is not alone in subscribing to the construction of imaginary 
‘for information’ worlds in health technology assessment. A 
significant proportion of single payer health systems also 
subscribe to this meme – to include Australia, Canada, Ireland, 
New Zealand the UK and the majority of European Union 
countries (with Germany a notable exception).  Unlike the 
situation of ICER in the US, the agencies responsible for 
evaluating reference case models in these countries have a 
legislative responsibility.  They can require a manufacturer to 
submit a reference case model, which is then subject to review 
both by the agency and by contracted third parties who have an 
established track record in assessing modeled imaginary 
reference case claims. ICER is alone in developing and releasing 
recommendations from its own model. Certainly, the model is 
accessible to stakeholders to review (subject to constraints) but 
there is no formal review process by a third party of the final 
proposed model.  This has to be a concern as there are a number 
of, primarily academic, centers in for example the UK (e.g., 
University of Sheffield) and in Australia (e.g., the University of 
Adelaide) with the necessary expertise. Whether this is worth 
doing is, of course, problematic as they would be asked to 
evaluate an imaginary world and potentially propose a modified 
or alternative imaginary world. This hardly seems to be a basis 
for advancing knowledge.    
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There is no reason for the US to embrace imaginary worlds that 
support hypothetical value assessments.  This applies in 
particular to the application of cost-per-QALY willingness to pay 
thresholds.  The fact that health systems outside the US are 
prepared to base decisions for pricing and access on the 
construction of imaginary worlds is no reason for the US to 
follow suit. In the case of SSTs, ICER faces a critical challenge. 
How can ICER adapt its reference case methodology when that 
methodology can be used to support one-off market entry cure 
pricing that ICER and other commentators might consider 
excessive? 
 
Importantly, as survivorship is the critical variable driving 
aggregate estimates of imaginary QALYs the choice and 
justification for the survivorship algorithm becomes of interest. 
While cure proportion based claims for QALYs would still fail the 
demarcation criteria, ICER’s choice of cure proportion 
application, in particular if viewed as a reference case ‘rescue’, 
would be a further point of contention between manufacturers, 
health systems and ICER. The more assumptions that are built 
into any model, even one that meets the required demarcation 
criteria, the greater the probability that the claims made are 
false. 
 
Next Steps 
It seems ridiculous, almost to the point of absurdity, to base 
formulary decisions for access and pricing on the construction of 
imaginary worlds. While ICER may see these fantasy constructs 
as the ‘state of the art’ in health technology assessment, it is a 
poor state of the art to put attempts at creating credible, 
evaluable and replicable claims for innovative products, 
especially those that are focused on rare disease and which 
might offer a one-off cures, to one side. This is not an insoluble 
problem. Previous commentaries in INNOVATIONS in Pharmacy 
have addressed this issue. The key point is that initiatives have 
to be taken to create and monitor platforms for ongoing therapy 
evaluations. Rather than speculate and then walk away in favor 
of creating the next imaginary world, it has been proposed that 
treatment center registry platforms be encouraged to monitor 
therapy response and the management of patients. An extensive 
proposal was made for the treatment of chronic pain, with 
particular emphasis on the abuse of pain medications such as 
opioids, together with proposals for platforms in behavioral 
health and medical marijuana 27 28 29 30 31 32 33. Indeed, the 
Program in Social and Administrative Pharmacy at the University 
of Minnesota has published guidelines for formulary evaluation 
that specifically address the need for manufacturers in making 
formulary decisions to propose and if necessary underwrite 
platforms that will capture the impact of therapies, reporting 
back to formulary committees in a meaningful time frame 34 35. 
It is proposed that, subject to peer review, future commentaries 
will address this issue in more detail while continuing to point 
out that creating imaginary worlds is hardly the basis for 
effective decision making. 
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